We all knew that 1/3 of the U.S. population was obese and that 1/3 of our kids are already obese. But, JAMA reports it’s much worse than that — over 1/3 of the U.S. population has metabolic syndrome. In other words, that belly bulge has already given 1/3 of the U.S. population type 2 diabetes and hypertension and narrowed their carotid arteries so they get a stroke or is going to! Not only scary but expensive. Until now, the only abdominal or belly fat we could remove was omental fat, a not an altogether benign procedure, but a procedure shown to improve metabolism. Mesenteric fat has been shown to be more metabolically hazardous than omental fat and its accumulation directly correlated with the severity of carotid narrowing. Endoscopic visceral lipectomy can give us a way to remove this fat safely and effectively for the very first time. BioSculpture Technology, Inc. (“BST”) filed its answer to a first round of SEC comments on its Form 1-A for a Tier 2 Reg. A Offering to fund development and clinical testing of its minimally invasive EVL® device for the endoscopic removal of visceral or “belly” fat, as a new treatment of obesity, metabolic syndrome and type 2 diabetes mellitus. We believe our patented technology and procedure, Endoscopic Visceral Lipectomy (“EVL”) to remove this noxious fat, illustrated in this 70 second medical video, will save and improve millions of lives each year, while significantly reducing healthcare costs.

August 9, 2016

medical video

 


BioSculpture Technology, Inc. (“BST”) filed its Form 1-A for a Tier 2 Reg. A Offering to fund development and clinical testing of its minimally invasive EVL® device for the endoscopic removal of visceral or “belly” fat, as a new treatment of obesity, metabolic syndrome and type 2 diabetes mellitus. Excessive visceral fat within the abdominal cavity causes metabolic syndrome and type 2 diabetes, shortening lives and decreasing their quality. We believe our patented technology and procedure, Endoscopic Visceral Lipectomy (“EVL”) to remove this noxious fat, illustrated in this 70 second medical video, will save and improve millions of lives each year, while significantly reducing healthcare costs. You can listen to the highlights of our investor presentation, place an Indication of Interest in our Offering, or contact us for an interim bridge financing opportunity for Accredited Investors.

July 25, 2016

www.biosculpturetechnology.com


Recorded April 11 Traders Network Interview of BioSculpture Technology’s CEO Dr. Robert Cucin

April 13, 2015

CEO, Robert L. Cucin is interviewed by Michael Yorba on the I Heart Radio’s “Traders Network Show” on April 11, 2015.

Dr. Cucin discusses the rationale and potential of the endoscopic visceral lipectomy methods and devices the company is developing for the treatment of obesity, metabolic syndrome and type 2 diabetes.


Our patented technology will make it possible to remove fat WITHIN the belly safely.

October 19, 2014

BioSculpture Technology’s patented technology now makes it possible to safely and efficiently remove visceral or “belly” fat inside the abdomen for the first time.  This method has the potential of becoming a safer and highly effective alternative to current bariatric surgical treatments of obesity, metabolic syndrome and type 2 diabetes mellitus.


November 8, 2013

November 5, 2013 Press Release U.S. Patent 8,574,223 issued protecting a Method of Collecting and In Situ Processing of Tissue Sampled from Human Patients During Aspiration Operations.

The patent describes a method and device that allows collection of processing of fat in isolated samples for analysis or autografting.

The clinical significance of this patent is that it facilitates and teaches the sampling of  fat to ascertain the location and collections of fat which are the most noxious, specifically those that are producing the cytokines or cellular hormones which are responsible for metabolic syndrome and the morbidities associated with obesity.

There is a vastly different metabolic significance of fat with the different body compartments, with visceral fat being the most hazardous, probably because of its drainage into the portal circulation.  Fat in different locations within each compartment is likely to vary in metabolic significance as well.   It is logical to adopt a “worst first” fat removal sequence to maximize any potential health benefits.


BioSculpture Technology, Inc. establishes Obesity Control Research & Development Division

October 21, 2013

October 21, 2013 – BioSculpture Technology establishes the Obesity Control Research and Development Division.  The Division will consolidate and expand current efforts to develop improved methods and devices for the treatment of obesity, metabolic syndrome, and type 2 Diabetes mellitus.

2/3 of affluent populations are overweight and 1/3 are frankly obese.  43% of Developed World is forecast to be      obese in 10 years.  Obesity related chronic diseases account for 75% of overall healthcare spending.  Those diseases include type 2 Diabetes mellitus, hypertension, heart disease, gastric reflux, sleep apnea, autoimmune diseases and cancer.   Those diseases don’t just shorten lives, they reduce the quality of life.

80% of Type II Diabetics are obese. 1 out of 5 healthcare dollars is spent on Diabetes mellitus. Diabetes is the most frequent cause of kidney failure requiring dialysis and a frequent cause of blindness.

Already embarked on the goal of developing alternative bariatric treatments of obesity, metabolic syndrome and type II Diabetes mellitus, BioSculpture Technology has had three U.S. Patents allowed and has numerous U.S. and foreign Applications pending in this area.  

 

 


Campaign to Kick Start Development of Less Invasive Obesity Treatment

June 24, 2013

BioSculpture Technology, Inc. initiates a campaign to kick start development of the treatment contemplated by two recently issued U.S. patents to endoscopically removal visceral fat.

Visceral fat is a noxious hormone factory secreting cytokines which make obese and overweight patients insulin resistant and develop type 2 diabetes mellitus, hypertension, slows their metabolism, and promotes coronary artery disease, inflammatory diseases and cancers.  The literature and some early clinical studies have shown removing it has immediately beneficial effects in reversing those metabolic effects.

Please take the time to learn more about this and help us bring it to the 1.3 billion people whom it can benefit faster.

http://www.indiegogo.com/project/445739/widget/3646746

 


BioSculpture Technology, Inc. has an important new patent issue.

January 11, 2013

January 8, 2013 – BioSculpture Technology’s licensed patent portfolio is strengthened by the issuance of U.S. Patent 8,348,929 B2Method of and Apparatus for Treating Abdominal Obesity and Metabolic Syndrome in Human Patients.

2/3 of the U.S. population is overweight and 1/3 is frankly obese.   43% of minorities are overweight today and 43% of the general population isf forecast to be obese in 10 years.  As 80% of obese patients develop type 2 Diabetes mellitus which is the leading cause of renal failure and a frequent cause of blindness, obesity is at the core of America’s burgeoning health care cost crisis.

This patent teaches a method and apparatus for endoscopic removal of visceral fat in a minimally invasive procedure that does not involve cutting into the bowel or leaving behind a foreign body.  As such it has the potential of replacing gastric restrictive surgeries (Lap Band or gastric sleeve procedures) or intestinal bypass procedures (roux-en-Y) with a less invasive procedure less fraught with potential complications and sequelae.  Insulin regulating drugs and hypertensive medication may not be needed as the metabolic syndrome is altered.

Visceral fat is a noxious hormone factory which “latches” the body into an abnormally low metabolic rate, an insulin resistant, hungry condition with inflammatory cytokines promoting heart attacks, strokes, autoimmune diseases and cancers.  Removal of small amounts of visceral fat helps the body return to a higher metabolic rate, have lowered insulin resistance, and the patient be less hungry.  A “multiplier” effect may follow with the loss of 7-10x as much body fat.  And the procedure may be repeated as needed without the risk of creating nutritional cripples.

At the very least this patent paves the way for less invasive alternatives which may supplement current modalities.


BioSculpture Technology, Inc. Private Placement

March 21, 2012

BST now has numerous pipeline products under development and 21 pending international andU.S.patent applications with claims relating to:

    • Improved TCAL designs for more efficient aspiration;
    • Synchronization of tumescence and bipolar cautery with aspiration;
    • Collection, concentration, processing, and reinjecting syringes and in-line chambers and methods;
    • Endoscopic fat removal devices and methods for treating abdominal obesity, metabolic syndrome, and type II Diabetes Mellitus.
    • An internet-based network supporting the harvesting, photoactivation, cataloguing, tracking, and managing of aspirated fat tissue samples including stem cells.
    • Device and method for photo-activating an aspirated sample of tissue within a tissue collection and processing system.              

            You can view BST product offerings, read a white paper discussing clinical results, a surgical video of them in use, and illustrative animations of twin cannula reciprocation and the Airbrush(R) Liposculptor II on the company website

             BST has engaged the Maxim Group as its investment banker to make a private placement of $10 Million Dollars its equity for the company’s expansion.


IN3 Medical Device Conference March 2, 2012 in Orlando

March 21, 2012

  BST was invited to present an update of its progress at Elsevier’s IN3 Medical Device 360 degrees March 2, 2012 at the Ritz-Carlton Orlando Grande Lakes in Orlando, Florida.